NorthWest Biotherapeutics Inc (NWBO)

[sentiment_stocks]

OH, and the PolyICLC arm was 44% IDH mutant. ~ Ex

There were NOOOOOOO IDH mutant GBM (IV) patients in this trial.
Zero.

There were four out of 15 methylated GBM patients in this trial. They were also the longest livers in the GBM set.

One was placebo (DCVax alone) and this patient lived to 61.2 months (so 5.1 years from beginning of treatment).

One was treatment with Poly ICLC (and DCVax) and this patient lived to 52.5 months (so 4.38 years from beginning of treatment)

Two were treatment with Resiquimod (and DCVax) and
one patient lived to 16.1 months (so 1.34 years from beginning of treatment)
second patient lived to 43.3 months (so 3.61 years from beginning of treatment)

See details below from the Patient Level Supplemental Chart found in the supplementary information.
These were all the GBM patients in the trial. See relevant details below chart.


PLACEBO
1.
S02-22-1
GBM
No IDH / Yes Methylated
OS: 61.2 months

2.
S06-44-1
GBM
No IDH / No Methylated
OS: 14.4 months

3.
S12-26-1
GBM
No IDH / No Methylated
OS: 5.5 months

4.
S22-041
GBM
No IDH / No Methylated
OS: 7.0 months

POLY ICLC
1.
S01-49-2
GBM
No IDH / No Methylated
OS: 26.6 months

2.
S03-05-2
GBM
No IDH / No Methylated
OS: 28.6 months

3.
S11-58-2
GBM
No IDH / Yes Methylated
OS: 52.5 months

4.
S16-07-2
GBM
No IDH / No Methylated
OS: 24.5 months

5.
S27-06-2
GBM
No IDH / No Methylated
OS: 28.6 months

RESIQUIMOD
1.
S05-94-3
GBM
No IDH / Yes Methylated
OS: 16.1 months

2.
S08-81-3
GBM
No IDH / No Methylated
OS: 16.7 months

3.
S13-23-3
GBM
No IDH / No Methylated
OS: 19.3 months

4.
S17-70-3
GBM
No IDH / Yes Methylated
OS: 43.3 months

5.
S23-64-3
GBM
No IDH / No Methylated
OS: 13.1 months

6.
S26-59-3
GBM
No IDH / No Methylated
OS: 33.3 months

mOS for DC + Poly-ICLC in GBM patients was a whopping 13 months. [Figure 3B]. ~ex

From the list of 5 Poly ICLC + DCVax-L patients, each of their OS were as follows:
24.5
26.6
28.6 median
28.6
52.5

So the median OS of the Poly ICLC GBM patients was 28.6, not 13... at least that's what the trial's patient level data shows. I think you were looking at the mPFS chart (not the mOS chart) when you accidentally pointed out that the mOS was 13. At least that's what it looks like to me when I looked at the chart (see below).



Well, it's been fun. :)